Patterns of increased incidence and survival of cutaneous melanoma in Girona (Spain) 1994–2013: a population-based study

Rubió‐Casadevall, Jordi; Puig-Vives, Montserrat; Puigdemont, Montse; Vilardell, L.; Carbó, Anna; Marcos‐Gragera, Rafael; Vilar-Coromina, N.

doi:10.1007/s12094-018-1900-x

Cited by 7 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, Northern European countries, which have a greater incidence than Southern countries, have a higher incidence/mortality ratio explained by the high level of awareness in these countries, where melanoma is diagnosed in earlier stages . This hypothesis is in line with a noticeable rise in the incidence rate of thin melanomas (Breslow < 1 mm and melanoma in situ ) in the last decades in Spain, increasing, by far, more than the incidence rate of invasive melanomas . At the same time, the trend of thick melanomas (>4 mm) appears to have levelled off .…”

Section: Discussionsupporting

confidence: 57%

“…[25][26][27] This hypothesis is in line with a noticeable rise in the incidence rate of thin melanomas (Breslow < 1 mm and melanoma in situ) in the last decades in Spain, increasing, by far, more than the incidence rate of invasive melanomas. [28][29][30] At the same time, the trend of thick melanomas (>4 mm) appears to have levelled off. 29,31 However, some authors have also hypothesized that the different trends between incidence and mortality could be due to the fact that some lesions diagnosed as melanoma could be biologically benign.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex‐specific age‐cohort‐period effects

Gutiérrez‐González

López‐Abente

Aragonés

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Mortality from malignant cutaneous melanoma increased alarmingly during the second half of the 20th century in Spain and other European countries. Objective The aim was to analyse sex‐ and age‐specific trends in melanoma mortality in Spain in the period 1982–2016. Methods European age‐standardized melanoma mortality rates during the period 1982–2016 were calculated from mortality figures provided by the National Statistics Institute. Joinpoint regressions were used to identify significant points of change in trends and to compute average annual per cent change (AAPC). Age‐cohort‐period models were fitted to explore the effect of these variables on mortality. Results During the period 1982–2016, age‐standardized melanoma mortality rates increased in Spain from 0.90 to 1.80 deaths per 100 000 people in men and from 0.64 to 1.11 per 100 000 in women, rising noticeably from 1982 to 1995 in both sexes and in all age groups. From the mid‐90s different trends were observed depending on sex and age: there was a decrease in mortality in the population younger than 45 years (AAPC ‐2 in both sexes) and aged 45–64 years (AAPC ‐1 among men and ‐0.2 among women), but in the group over 64 years rates continued to increase (AAPC 1.7 and 0.2, respectively, for men and women). The mortality sex ratio decreased in the younger population but increased in older individuals. A cohort effect was observed with lower mortality in the cohorts born after 1943 in men and 1956 in women. There was also a period effect with decreased mortality rates at the beginning of the 1990s. Conclusions Melanoma mortality rates in Spain increased during the last decades of the 20th century; however, later they stabilized in women and began to decrease in younger cohorts and middle‐aged men. Promotion of primary and secondary prevention measures should continue, with particular emphasis on males over 65 years.

show abstract

Section: Discussionsupporting

confidence: 57%

Section: Discussionmentioning

confidence: 96%

Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex‐specific age‐cohort‐period effects

Gutiérrez‐González

López‐Abente

Aragonés

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Diagnosis and treatment strategies for melanoma patients have evolved over the last two decades to optimise staging, locoregional disease control and survival, as well as to minimise morbidity from treatment side effects (Rosko, Vankoevering, McLean, Johnson, & Moyer, ). Despite these advances, significant improvement in survival has not yet been achieved in Spain (Allemani et al, ; Chirlaque et al, ; Rubió‐Casadevall et al, ). According to the results of the CONCORD‐3 study, the 5‐year net survival for patients diagnosed in 2010–2014 was 86.8%, similar to that found in other Southern European countries such as Italy and Portugal, but with no significant increase as compared to the 85.3% survival in patients diagnosed in 2000–2004 (Allemani et al, ).…”

Section: Introductionmentioning

confidence: 99%

Disparities in the management of cutaneous malignant melanoma. A population‐based high‐resolution study

et al. 2019

View full text Add to dashboard Cite

Population‐based cancer registry data from three Spanish areas were used to assess the patterns of care and adherence to guidelines for cutaneous malignant melanoma. We included 934 cases diagnosed in 2009–2013. Completeness of the pathology reports, imaging for detecting distant metastasis and the use of sentinel lymph node biopsy (SLNB) were analysed. The proportion of pathology reports that mentioned the essential pathological features required for T staging was 93%, ranging across geographic areas from 81% to 98% (p < 0.001). The percentage of low‐risk patients who underwent no imaging studies, as proposed by guidelines, or only chest imaging ranged among areas from 0.6% to 84% (p < 0.001). Of the patients with clinically node‐negative melanoma >1 mm thick and no distant metastases, 68% underwent SLNB, varying by area from 61% to 78% (p = 0.017). This study revealed wide geographic variation in different aspects of melanoma care. The use of a standardised structured pathology report could strengthen the completeness of reporting. Improvement strategies should also include efforts to reduce overuse of imaging in low‐risk patients and to increase the adherence to guidelines recommendations on the use of SLNB.

show abstract

“…This subtype is generally associated with an excellent prognosis in Europe, North America and Oceania, as has been shown in previous studies. 13,14,29,33 Several international studies have shown an increasing incidence of thinner melanomas (1 mm or less) 15,[34][35][36][37][38][39][40] as a result of raised public awareness and earlier detection, especially for superficial spreading melanomas. The result is an increasing number of people with melanoma who are less likely to die as a result of their tumours.…”

Section: Discussionmentioning

confidence: 99%

Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000–2014 in 59 countries (CONCORD-3)

Carlo

Stiller

Eisemann

et al. 2022

British Journal of Dermatology

View full text Add to dashboard Cite

Background CONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000-2014. Clinical evidence suggests marked international differences in the proportion of lethal acral and nodular subtypes of cutaneous melanoma. Objectives We aimed to assess whether the differences in morphology may explain global variation in survival. Methods Patients with melanoma were grouped into the following seven morphological categories: malignant melanoma, not otherwise specified (International Classification of Diseases for Oncology, third revision morphology code 8720), superficial spreading melanoma (8743), lentigo maligna melanoma (8742), nodular melanoma (8721), acral lentiginous melanoma (8744), desmoplastic melanoma (8745) and other morphologies (8722-8723, 8726-8727, 8730, 8740-8741, 8746, 8761, 8770-8774, 8780). We estimated net survival using the nonparametric Pohar Perme estimator, correcting for background mortality

show abstract

Patterns of increased incidence and survival of cutaneous melanoma in Girona (Spain) 1994–2013: a population-based study

Abstract: We found an increasing trend in the incidence of low-risk melanoma and a survival rate similar to that reported elsewhere in Europe.

Cited by 7 publications

References 24 publications

Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex‐specific age‐cohort‐period effects

Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex‐specific age‐cohort‐period effects

Disparities in the management of cutaneous malignant melanoma. A population‐based high‐resolution study

Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000–2014 in 59 countries (CONCORD-3)

Contact Info

Product

Resources

About